Buscar
Enlivex Therapeutics Ltd
ENLVAñadir a la lista de seguimiento
1.580USD
0.0000.00%
Horarios del mercado （ET）Cotizaciones retrasadas 15 min
25.00MCap. mercado
0.06P/E TTM
Más Datos de Enlivex Therapeutics Ltd Compañía
Enlivex Therapeutics Ltd is an Israel-based clinical stage macrophage reprogramming immunotherapy company developing Allocetra, off-the-shelf cell therapy designed to reprogram macrophages into their homeostatic state. AllocetraTM is a therapy designed to reprogram macrophages into their homeostatic state. Diseases such as solid cancers, sepsis, COVID-19 and many others reprogram macrophages out of their homeostatic state. These non-homeostatic macrophages contribute significantly to the severity of the respective diseases. By restoring macrophage homeostasis, AllocetraTM has the potential to provide immunotherapeutic mechanism of action for life-threatening clinical indications that are defined as unmet medical needs, as a stand-alone therapy or in combination with therapeutic agents.
Perfil de Enlivex Therapeutics Ltd
Símbolo de cotizaciónENLV
Nombre de la empresaEnlivex Therapeutics Ltd
Fecha de salida a bolsaJul 30, 2014
Director ejecutivoHershkovitz (Oren)
Número de empleados36
Tipo de seguridadOrdinary Share
Fin del año fiscalJul 30
Dirección14 Einstein St.
CiudadNESS-ZIONA
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísIsrael
Código postal7403618
Teléfono97286623301
Sitio Webhttps://www.enlivex.com/
Símbolo de cotizaciónENLV
Fecha de salida a bolsaJul 30, 2014
Director ejecutivoHershkovitz (Oren)
Ejecutivos de Enlivex Therapeutics Ltd
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Shai A. Novik
Mr. Shai A. Novik
Executive Chairman of the Board
Executive Chairman of the Board
464.93K
+87.69%
Mr. Shai A. Novik
Mr. Shai A. Novik
Executive Chairman of the Board
Executive Chairman of the Board
464.93K
+87.69%
Dr. Abraham (Avri) Havron, Ph.D.
Dr. Abraham (Avri) Havron, Ph.D.
Independent Director
Independent Director
12.22K
+1.05%
Dr. Abraham (Avri) Havron, Ph.D.
Dr. Abraham (Avri) Havron, Ph.D.
Independent Director
Independent Director
12.22K
+1.05%
Mrs. Shachar Shlosberger, CPA
Mrs. Shachar Shlosberger, CPA
Chief Financial Officer
Chief Financial Officer
2.01K
+78.69%
Mrs. Shachar Shlosberger, CPA
Mrs. Shachar Shlosberger, CPA
Chief Financial Officer
Chief Financial Officer
2.01K
+78.69%
Dr. Gili Hart, Ph.D.
Dr. Gili Hart, Ph.D.
Independent Director
Independent Director
481.00
+26.61%
Dr. Gili Hart, Ph.D.
Dr. Gili Hart, Ph.D.
Independent Director
Independent Director
481.00
+26.61%
Mr. Sangwoo Lee
Mr. Sangwoo Lee
Director
Director
--
--
Dr. Bernhard Jurgen Kirschbaum, Ph.D.
Dr. Bernhard Jurgen Kirschbaum, Ph.D.
Director
Director
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Shai A. Novik
Mr. Shai A. Novik
Executive Chairman of the Board
Executive Chairman of the Board
464.93K
+87.69%
Mr. Shai A. Novik
Mr. Shai A. Novik
Executive Chairman of the Board
Executive Chairman of the Board
464.93K
+87.69%
Dr. Abraham (Avri) Havron, Ph.D.
Dr. Abraham (Avri) Havron, Ph.D.
Independent Director
Independent Director
12.22K
+1.05%
Dr. Abraham (Avri) Havron, Ph.D.
Dr. Abraham (Avri) Havron, Ph.D.
Independent Director
Independent Director
12.22K
+1.05%
Mrs. Shachar Shlosberger, CPA
Mrs. Shachar Shlosberger, CPA
Chief Financial Officer
Chief Financial Officer
2.01K
+78.69%
Mrs. Shachar Shlosberger, CPA
Mrs. Shachar Shlosberger, CPA
Chief Financial Officer
Chief Financial Officer
2.01K
+78.69%
Preguntas frecuentes
¿Quiénes son los cinco principales accionistas de Enlivex Therapeutics Ltd?
Los cinco principales accionistas de Enlivex Therapeutics Ltd son: Mr. Shai A. Novik
¿Cuántas instituciones poseen acciones de Enlivex Therapeutics Ltd (ENLV)?
A fecha de 2026Q1, 44 instituciones poseen acciones de Enlivex Therapeutics Ltd, con un valor de mercado combinado de aproximadamente 2.13M, lo que representa el 0.89% del total de acciones. En comparación con el 2025Q4, el accionariado institucional ha aumentado en -1519291.00.